Meza-Reyes G, Aldrete-Velasco J, Espinosa-Morales R, Torres-Roldán F, Díaz-Borjón A, Robles-San Román M

Language: Spanish
References: 22
Page: 67-75
PDF size: 325.17 Kb.

ABSTRACT

In the modern world, among the different clinical presentations of osteoarthritis, gonarthrosis and coxarthrosis exhibit the highest prevalence. In this paper, the characteristics of osteoarthritis and the different scales of assessment and classification of this pathology are exposed, to provide an exhibition of current evidence generated around diagnostic algorithms and treatment of osteoarthritis, with emphasis set out in the knee and hip, as these are the most frequent; a rational procedure for monitoring patients with osteoarthritis based on characteristic symptoms and the severity of the condition is also set. Finally, reference is made to the therapeutic benefits of the recent introduction of viscosupplementation with Hylan GF-20.

REFERENCES

1. Ayhan E, Kesmezacar H, Akgun I. Intraarticular injections (corticosteroid, hyaluronic acid, platelet rich plasma) for the knee osteoarthritis. World J Orthop. 2014;5(3):351-61.

2. Espinosa-Morales R, Arce-Salinas CA, Cajigas- Melgoza JC. Reunión multidisciplinaria de expertos para el diagnóstico y tratamiento de la osteoartritis: actualización basada en la evidencia. Med Int Méx. 2013;29(1):67-94.

3. Singh AK, Kalaivani M, Krishnan A. Prevalence of osteoarthritis of knee among elderly persons in urban slums using American College of Rheumatology (ACR) criteria. J Clin Diagn Res. 2014;8(9):JC09-11.

4. Hunter DJ. Viscosupplementation for osteoarthritis of the knee. N Engl J Med. 2015;372:1040-7.

5. Neogi T. The epidemiology and impact of pain in osteoarthritis. Osteoarthritis Cartilage. 2013;21(9):1145-53.

6. Ministerio de Salud (MinSal) del Gobierno de Chile. Tratamiento médico en personas de 55 años y más con artrosis de cadera y/o rodilla, leve o moderada. MinSal, Santiago de Chile, 2009.

7. American Academy of Orthopaedic Surgeons (AAOS). Treatment of osteoarthritis of the knee (nonarthroplasty), full guideline. AAOS, Rosemont (Illinois, USA), 2008.

8. Wright RW. Osteoarthritis classification scales: interobserver reliability and arthroscopic correlation. J Bone Joint Surg Am. 2014;96(14):1145-1151.

9. Peña Ayala AH, Fernández-López JC. Prevalencia y factores de riesgo de la osteoartritis. Reumatol Clin. 2007;3(Supl 3):S6-12.

10. Mies Richie A, Francis ML. Diagnostic approach to polyarticular joint pain. Am Fam Physician. 2003;68(6):1151-60.

11. Hochberg MC, Altman RD, Toupin-April K, Benkhalti M, Guyatt G, McGowan J. American College of Rheumatology 2012 Recommendations for the use of nonpharmacologic and pharmacologic therapies in osteoarthritis of the hand, hip, and knee. Arthritis Care Res. 2012;64(4):465-74.

12. American Academy of Orthopaedic Surgeons (AAOS). Treatment of osteoarthritis of the knee, evidence-based guideline. AAOS, Rosemont (Illinois, USA), 2nd ed., 2013.

13. Jordan KM, Arden NK, Doherty M, Bannwarth B, Bijlsma JWJ, Dieppe P et al. European League Against Rheumatism (EULAR) Recommendations 2003: an evidence based approach to the management of knee osteoarthritis: report of a Task Force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT). Ann Rheum Dis. 2003;62:1145-55.

14. Zhang W, Doherty M, Arden N, Bannwarth B, Bijlsma J, Gunther KP et al. European League Against Rheumatism (EULAR) evidence based recommendations for the management of hip osteoarthritis: report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis. 2005;64:669-81.

15. MacDonald KV, Sanmartin C, Langlois K, Marshall DA. Symptom onset, diagnosis and management of osteoarthritis. Health Reports. 2014;25(9):10-7.

16. Wang Y, Hall S, Hanna F, Wluka AE, Grant G, Marks P et al. Effects of Hylan G-F 20 supplementation on cartilage preservation detected by magnetic resonance imaging in osteoarthritis of the knee: a twoyear single-blind clinical trial. BMC Musculoskel Dis. 2011;12:195 (1-9).

17. Migliore A, Giovannangeli F, Granata M, Laganà B. Hylan GF-20: review of its safety and efficacy in the management of joint pain in osteoarthritis. Clin Med Insights Arthritis Musculoskelet Disord. 2010;3:55-68.

18. Van den Bekerom MPJ, Rys B, Mulier M. Viscosupplementation in the hip: evaluation of hyaluronic acid formulations. Arch Orthop Trauma Surg. 2008;128:275-80.

19. Migliore A, Bizzi E, Massafra U et al. The impact of treatment with Hylan GF 20 on progression to total hip arthroplasty in patients with symptomatic hip OA: a retrospective study. Curr Med Res Opin. 2012;28(5):75560.

20. Migliore A, Bizzi E, Massafra U, et al. The impact of treatment with Hylan GF 20 on progression to total hip arthroplasty in patients with symptomatic hip OA: a retrospective study. Curr Med Res Opin. 2012;28(5):75560.

21. Chevalier X, Jerosch J, Goupille P et al. Single, intraarticular treatment with 6 mL Hylan G-F 20 in patients with symptomatic primary osteoarthritis of the knee: a randomised, multicentre, double-blind, placebo controlled trial. Ann Rheum Dis. 2010;69:113-9.

22. Waddell DD, Bricker DWC. Total knee replacement delayed with Hylan G-F 20 use in patients with grade IV osteoarthritis. J Manag Care Pharm. 2007;13(2):113-21.